COVID-19: Hydroxychloroquine & Azithromycin / Anosmia / The Aerosolized vs. Droplet Debate (Recorded 3/24/20, 18:00 MST)

The circumstances surrounding the COVID-19 virus are quickly evolving and that means that EMM will have to as well. For the foreseeable future, EMM will be releasing COVID-19 updates. In this series, we will report the most recent statistics, summarize the newest literature and answer YOUR burning questions. Submit your questions through comments on this post or through private messages on any of our social media platforms.

Host: Elizabeth Esty, MD

Research By: Elizabeth Esty, Jackson Roos, Nathan Novotny & Mason Tuttle

Time Stamps:

0:00 - COVID-19 by the numbers

2:50 - Hydroxychloroquine and Azithromycin

6:05 - Ongoing Anti-Viral Therapy Research

7:47 - Anosmia

9:31 - Viability of COVID-19 Aerosolized vs. on Surfaces

10:49 - Listener Questions

References:

[1] The Center for Systems Science and Engineering (CSSE) at Johns Hopkins University Interactive Map

[2] Gautret et al. (2020) Hydroxychloroquine and azithromycin as a treatment of COVID‐19: results of an open‐label nonrandomized clinical trial. International Journal of Antimicrobial Agents – In Press 17 March 2020 –DOI : 10.1016/j.ijantimicag.2020.105949

[3] Belhadi D, Peiffer-Smadja N, Yazdanpanah Y, Mentré F, Laouénan C. A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19. medRxiv. March 2020:2020.03.18.20038190.doi:10.1101/2020.03.18.20038190

[4] Hopkins C, Kumar N, ENT UK at The Royal College of Surgeons of England. Loss of sense of smell as marker of COVID-19 infection. https://www.entuk.org/sites/default/files/files/Loss%20of%20sense%20of%20smell%20as%20marker%20of%20COVID.pdf.